BeOne Medicines Ltd. (ONC) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Pharmaceuticals Branche. Der aktuelle CEO ist John V. Oyler.
ONC hat IPO-Datum 2016-02-02, 11,000 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $33.13B.
BeOne Medicines is a global oncology company dedicated to discovering, developing, and commercializing innovative cancer therapies. Originally founded as BeiGene in 2010, the company rebranded to BeOne in late 2024 and relocated its headquarters to Basel, Switzerland in 2025, now operating across over 45 countries. The company has established market leadership in immuno-oncology and targeted therapies, with flagship products including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications worldwide, and Brukinsa (zanubrutinib), a BTK inhibitor that generates over $1.3 billion in annual sales across the U.S., Europe, and China. BeOne's strategy combines internal research and development with externally sourced assets to build a robust pipeline targeting hematologic malignancies and solid tumors.
